Substituted pyridone compounds and methods of use
    1.
    发明授权
    Substituted pyridone compounds and methods of use 失效
    取代的吡啶酮化合物和使用方法

    公开(公告)号:US07700607B2

    公开(公告)日:2010-04-20

    申请号:US11879830

    申请日:2007-07-18

    IPC分类号: A61K31/517

    CPC分类号: C07D471/04 C07D401/04

    摘要: The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I wherein R1-6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

    摘要翻译: 本发明包括能够调节c-kit受体的新一类化合物,因此可用于治疗c-kit介导的疾病,包括各种炎性,纤维化和/或肥大细胞介导的疾病如肥大细胞增多症。 化合物具有通式I,其中R1-6在本文中定义。 本发明还包括药物组合物,用于治疗c-kit介导的疾病的方法,以及可用于制备本发明化合物的中间体和方法。

    Substituted pyridone compounds and methods of use
    3.
    发明申请
    Substituted pyridone compounds and methods of use 失效
    取代的吡啶酮化合物和使用方法

    公开(公告)号:US20080249090A1

    公开(公告)日:2008-10-09

    申请号:US11879830

    申请日:2007-07-18

    CPC分类号: C07D471/04 C07D401/04

    摘要: The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I wherein A0-3 and R1-6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

    摘要翻译: 本发明包括能够调节c-kit受体的新一类化合物,因此可用于治疗c-kit介导的疾病,包括各种炎性,纤维化和/或肥大细胞介导的疾病如肥大细胞增多症。 这些化合物具有通式I,其中A 0-3和R 6-16在本文中定义。 本发明还包括药物组合物,用于治疗c-kit介导的疾病的方法,以及可用于制备本发明化合物的中间体和方法。

    Substituted Pyridone Compounds and Methods of Use
    4.
    发明申请
    Substituted Pyridone Compounds and Methods of Use 失效
    取代的吡啶酮化合物和使用方法

    公开(公告)号:US20100160312A1

    公开(公告)日:2010-06-24

    申请号:US12711167

    申请日:2010-02-23

    CPC分类号: C07D471/04 C07D401/04

    摘要: The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I wherein A0-3 and R1-6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

    摘要翻译: 本发明包括能够调节c-kit受体的新一类化合物,因此可用于治疗c-kit介导的疾病,包括各种炎性,纤维化和/或肥大细胞介导的疾病如肥大细胞增多症。 化合物具有通式I,其中A0-3和R1-6在本文中定义。 本发明还包括药物组合物,用于治疗c-kit介导的疾病的方法,以及可用于制备本发明化合物的中间体和方法。

    Substituted pyridone compounds and methods of use
    7.
    发明授权
    Substituted pyridone compounds and methods of use 失效
    取代的吡啶酮化合物和使用方法

    公开(公告)号:US08063055B2

    公开(公告)日:2011-11-22

    申请号:US12711167

    申请日:2010-02-23

    IPC分类号: A61K31/517

    CPC分类号: C07D471/04 C07D401/04

    摘要: The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I wherein A0-3 and R1-6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

    摘要翻译: 本发明包括能够调节c-kit受体的新一类化合物,因此可用于治疗c-kit介导的疾病,包括各种炎性,纤维化和/或肥大细胞介导的疾病如肥大细胞增多症。 化合物具有通式I,其中A0-3和R1-6在本文中定义。 本发明还包括药物组合物,用于治疗c-kit介导的疾病的方法,以及可用于制备本发明化合物的中间体和方法。

    Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
    8.
    发明授权
    Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use 有权
    螺氨基 - 咪唑稠合杂环化合物作为β-分泌酶调节剂和使用方法

    公开(公告)号:US08962859B2

    公开(公告)日:2015-02-24

    申请号:US13982096

    申请日:2012-02-13

    CPC分类号: C07D491/20 A61K31/353

    摘要: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A1, A3, A5, A6, A8, R2, R7, X, Y and Z of Formula I are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to plaque formation and deposition, resulting from the activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits and impairments, schizophrenia and other central nervous system conditions and disorders. The invention further provides compounds of Formulas II and III, and of sub-formulas of Formulas I, II and III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.

    摘要翻译: 本发明提供了一类可用于调节β-分泌酶(BACE)活性的化合物。 化合物具有通式I:其中式I的变量A1,A3,A5,A6,A8,R2,R7,X,Y和Z如本文所定义。 本发明还提供包含该化合物的药物组合物,以及用于治疗由于BACE的活性而导致的斑块形成和沉积相关疾病和/或病症的化合物和组合物的相应用途。 这种BACE介导的病症包括例如阿尔茨海默病,认知缺陷和损伤,精神分裂症和其他中枢神经系统病症和障碍。 本发明还提供了式II和III的化合物和式I,II和III的分子式,可用于制备式I-III化合物的中间体和方法和方法。

    Aurora kinase modulators and method of use
    9.
    发明授权
    Aurora kinase modulators and method of use 失效
    极光激酶调节剂和使用方法

    公开(公告)号:US08404694B2

    公开(公告)日:2013-03-26

    申请号:US12933400

    申请日:2009-03-19

    CPC分类号: C07D487/04

    摘要: The present invention relates to chemical compounds having a general formula I wherein A1-5 and 7-8, D′, L1, L2, R1, R3, R6-8, n and o are defined herein, and synthetic intermediates, which are capable of modulating the activity of Aurora kinase proteins and, thereby, influencing various disease states and conditions related to the activities of Aurora kinases. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

    摘要翻译: 本发明涉及具有通式I的化合物,其中A1-5和7-8,D',L1,L2,R1,R3,R6-8,n和o如本文所定义,和合成中间体,其能够 调节极光激酶蛋白的活性,从而影响与极光激酶活性相关的各种疾病状态和状况。 例如,化合物能够影响细胞周期和细胞增殖的过程,以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物,包括该化合物,以及治疗与Aurora激酶活性有关的疾病状态的方法。